Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
You may also be interested in...
Prestara Changes Course: Development To Focus on Lupus Signs And Symptoms
Genelabs will no longer pursue a Prestara indication for prevention of loss of bone mineral density in women with lupus.
Prestara Changes Course: Development To Focus on Lupus Signs And Symptoms
Genelabs will no longer pursue a Prestara indication for prevention of loss of bone mineral density in women with lupus.
GSK To Develop LymphoStat-B With Human Genome Sciences
Human monoclonal antibody is in clinical development for the treatment of rheumatoid arthritis and systematic lupus erythematosus. The two firms will share jointly in Phase III and IV development costs, as well as in sales and profits.